<DOC>
	<DOCNO>NCT00236145</DOCNO>
	<brief_summary>The primary objective study determine whether test titration regimen ACTIQ treatment reduce number inadequately manage episode breakthrough pain individual patient attain successful dose ACTIQ treatment quickly . The successful ACTIQ dose provide satisfactory combination efficacy tolerability single administration , assess patient .</brief_summary>
	<brief_title>Evaluate Efficacy Safety ACTIQ Patients With Cancer Breakthrough Pain</brief_title>
	<detailed_description />
	<mesh_term>Breakthrough Pain</mesh_term>
	<mesh_term>Fentanyl</mesh_term>
	<mesh_term>Citric Acid</mesh_term>
	<criteria>Patients include study follow criterion meet : patient least 18 year old woman must surgically sterile , 2 year postmenopausal , childbearing potential , must use medically accept method birth control ( ie , barrier method spermicide , steroidal contraceptive [ oral , implanted , DepoProvera contraceptives must use conjunction barrier method ] , intrauterine device ) patient experience persistent pain associated cancer cancer treatment least 7 day enrolment , patient take either equivalent 60 1000 mg/day oral morphine aroundtheclock ( ATC ) 25 300 micrograms/hr transdermal fentanyl treat persistent pain patient regularly experience 1 4 episode cancerrelated BTP per day take ATC opioid therapy patient experience least partial relief cancer relate BTP administer conventional opioid BTP medication dose approximately range onefifth onesixth 24hour sustain release dose patient capable selfadministering ACTIQ suck lozenge , produce sufficient saliva dissolve lozenge 15 minute , swallow saliva responsible adult caregiver available assist patient case emergency patient take ACTIQ home patient willingly provide informed consent participate study Patients exclude participate study 1 follow criterion meet : patient experience uncontrolled rapidly escalate pain , determine investigator , ATC administration pain medication might expect change first last administration ACTIQ . patient know suspected hypersensitivity and/or allergy fentanyl patient recent history current evidence abuse alcohol drug substance , licit collection patient neurological psychiatric disease sufficient , investigator 's opinion , compromise data collection patient receive strontium89 therapy within 6o day prior enter study patient receive therapy ( eg , radiotherapy ) within 1 week period prior enter study , investigator 's opinion , could alter pain response pain medication patient moderate severe oral mucositis patient pregnant , nursing , childbearing potential take adequate contraceptive measure patient previously treat ACTIQ patient participate trial unapproved drug previous 8 week patient diagnose either severe respiratory depression severe obstructive lung condition patient use monoamineoxidase inhibitor ( MAOI 's ) within 2week period prior enter study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2005</verification_date>
	<keyword>BTP</keyword>
	<keyword>Break pain</keyword>
	<keyword>breakthrough pain</keyword>
</DOC>